Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

OBJECTIVE : To evaluate the efficacy of the B-cell lymphoma 2 (BCL2)-inhibitor venetoclax in combination therapy for relapsed acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS : We retrospectively analyzed 7 adults with relapsed AML w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Feng, Yueqian, Dong, Changwei, Li, Zhihui, Wu, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia-Pacific Blood and Marrow Transplantation Group 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847272/
https://www.ncbi.nlm.nih.gov/pubmed/36711057
http://dx.doi.org/10.31547/bct-2020-025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847272/
https://www.ncbi.nlm.nih.gov/pubmed/36711057
http://dx.doi.org/10.31547/bct-2020-025

Ejemplares similares